204 related articles for article (PubMed ID: 36168049)
1. Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome.
Brierley SM; Greenwood-Van Meerveld B; Sarnelli G; Sharkey KA; Storr M; Tack J
Nat Rev Gastroenterol Hepatol; 2023 Jan; 20(1):5-25. PubMed ID: 36168049
[TBL] [Abstract][Full Text] [Related]
2. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome.
Storr MA; Yüce B; Andrews CN; Sharkey KA
Neurogastroenterol Motil; 2008 Aug; 20(8):857-68. PubMed ID: 18710476
[TBL] [Abstract][Full Text] [Related]
3. Role of cannabis in digestive disorders.
Goyal H; Singla U; Gupta U; May E
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):135-143. PubMed ID: 27792038
[TBL] [Abstract][Full Text] [Related]
4. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
Russo EB
Neuro Endocrinol Lett; 2004; 25(1-2):31-9. PubMed ID: 15159679
[TBL] [Abstract][Full Text] [Related]
5. Medical Use of Cannabinoids.
Fraguas-Sánchez AI; Torres-Suárez AI
Drugs; 2018 Nov; 78(16):1665-1703. PubMed ID: 30374797
[TBL] [Abstract][Full Text] [Related]
6. Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy.
Pandey S; Kashif S; Youssef M; Sarwal S; Zraik H; Singh R; Rutkofsky IH
Complement Ther Med; 2020 Jan; 48():102242. PubMed ID: 31987224
[TBL] [Abstract][Full Text] [Related]
7. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
Smith SC; Wagner MS
Neuro Endocrinol Lett; 2014; 35(3):198-201. PubMed ID: 24977967
[TBL] [Abstract][Full Text] [Related]
8. Chronic abdominal pain in irritable bowel syndrome - current and future therapies.
Zielińska A; Sałaga M; Włodarczyk M; Fichna J
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):729-739. PubMed ID: 29957084
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids and the gut: new developments and emerging concepts.
Izzo AA; Sharkey KA
Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
[TBL] [Abstract][Full Text] [Related]
10. Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases.
Ceuleers H; Van Spaendonk H; Hanning N; Heirbaut J; Lambeir AM; Joossens J; Augustyns K; De Man JG; De Meester I; De Winter BY
World J Gastroenterol; 2016 Dec; 22(47):10275-10286. PubMed ID: 28058009
[TBL] [Abstract][Full Text] [Related]
11. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
Tack J
Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):21-6. PubMed ID: 23859757
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid pharmacology and therapy in gut disorders.
Uranga JA; Vera G; Abalo R
Biochem Pharmacol; 2018 Nov; 157():134-147. PubMed ID: 30076849
[TBL] [Abstract][Full Text] [Related]
13. Gut feelings about the endocannabinoid system.
Di Marzo V; Piscitelli F
Neurogastroenterol Motil; 2011 May; 23(5):391-8. PubMed ID: 21481098
[TBL] [Abstract][Full Text] [Related]
14. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms.
Elsenbruch S
Brain Behav Immun; 2011 Mar; 25(3):386-94. PubMed ID: 21094682
[TBL] [Abstract][Full Text] [Related]
15. Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease?
Ambrose T; Simmons A
J Crohns Colitis; 2019 Mar; 13(4):525-535. PubMed ID: 30418525
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pain symptoms in irritable bowel syndrome patients.
Gupta V; Moshiree B; Verne GN
Drugs Today (Barc); 2004 Oct; 40(10):829-36. PubMed ID: 15605117
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
Cristino L; Bisogno T; Di Marzo V
Nat Rev Neurol; 2020 Jan; 16(1):9-29. PubMed ID: 31831863
[TBL] [Abstract][Full Text] [Related]
18. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome.
Keszthelyi D; Troost FJ; Masclee AA
Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(2):G141-54. PubMed ID: 22595988
[TBL] [Abstract][Full Text] [Related]
19. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.
Hasenoehrl C; Taschler U; Storr M; Schicho R
Neurogastroenterol Motil; 2016 Dec; 28(12):1765-1780. PubMed ID: 27561826
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in pharmacological treatment of irritable bowel syndrome.
Lazaraki G; Chatzimavroudis G; Katsinelos P
World J Gastroenterol; 2014 Jul; 20(27):8867-85. PubMed ID: 25083060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
